To gain more insight into the role of NFκB signaling and its pro-survival BCL-2 target genes in MM, we used the novel signal transduction pathway activity (STA) model that was described by Verhaegh et al. and Van de Stolpe et al. [20,21]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.